Share Email Print
cover

Proceedings Paper • new

Multifunctional polysilsesquioxane nanoparticle-based platform for the treatment of triple-negative breast cancer in vitro and in vivo using chemo and photodynamic therapy (Conference Presentation)

Paper Abstract

Multifunctional hybrid nanoparticles are being developed to carry a wide variety of therapeutic and imaging agents for multiple biomedical applications. Polysilsesquioxane (PSilQ) nanoparticles is a promising hybrid platform with numerous advantages to be used as delivery system for photodynamic therapy. In this work, we developed a redox-responsive PSilQ-based platform to transport and deliver simultaneously protoporphyrin IX (PpIX) and curcumin inside human cells. These PSilQ nanoparticles contain a high loading of PpIX (24.4 ± 2.5 %wt) and curcumin (7.6 ± 1.5 %wt), and are biodegraded inside cancer cells due to the high reducing environment. This multimodal delivery system shows a synergistic performance for the combined photo- and chemotherapy of the triple-negative breast cancer (TNBC) MDA-MB-231 cells. The safety and phototherapeutic efficacy of this PSilQ-based platform was evaluated in an orthotopic mice model of TNBC. The PSilQ nanoparticles are completely biodegraded and excreted from mice without any side effect. The efficacy data show that the PSilQ nanoparticles efficiently reduce tumor growth in the orthotopic mice model of TNBC. This work demonstrates that PSilQ nanoparticle-based platform is an excellent alternative for the combined photo- and chemotherapy of TNBC.

Paper Details

Date Published: 14 August 2019
PDF
Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 1107042 (14 August 2019); doi: 10.1117/12.2525973
Show Author Affiliations
Juan L. Vivero-Escoto, The Univ. of North Carolina at Charlotte (United States)
Zachary Lyles, The Univ. of North Carolina at Charlotte (United States)


Published in SPIE Proceedings Vol. 11070:
17th International Photodynamic Association World Congress
Tayyaba Hasan, Editor(s)

© SPIE. Terms of Use
Back to Top